RxDoctor Payments Data

Steve Han, MD

Neurology · Boston, MANPI 1912495813

Payments from drug & device makers

$2,325in general payments, 2019–2025

Across 84 payments — averaging $27.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$500
  • Teva Pharmaceuticals USA, Inc.$288
  • Ipsen Biopharmaceuticals, Inc$268
  • AbbVie$223
  • MDD US Operations, LLC$222
  • Neurocrine Biosciences, Inc.$175
  • plus $650 from 6 others

What the payments were for

  • Food & beverage$2,05788%
  • Education$26812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,325 in reported general payments places this provider in the 60th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$74,652
Medicare patients
281
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa13$47,694
GocovriAmantadine Hcl11$28,916
BotoxOnabotulinumtoxina18$12,823
Carbidopa-LevodopaCarbidopa/Levodopa258$10,008
Rasagiline Mesylate17$4,622
Carbidopa-Levodopa ErCarbidopa/Levodopa56$4,358
Entacapone15$4,231
AmantadineAmantadine Hcl56$2,816
Propranolol Hcl ErPropranolol Hcl16$1,378
Gabapentin93$1,351
Primidone43$1,058
Propranolol Hcl30$800
Levetiracetam28$720
Clonazepam63$391
Quetiapine Fumarate28$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$500$47,69413 claims
MDD US Operations, LLCGocovri$222$28,91611 claims
AbbVieBotox$223$12,82318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →